JUBLPHARMA vs KREBSBIO: Stock Comparison

JUBILANT PHARMOVA vs KREBS BIOCHEMICALS & INDUpdated 4 Sept 26, 4:08 PM ISTNSE & company filings

JUBILANT PHARMOVA is the larger company by market capitalisation. JUBILANT PHARMOVA shows a higher dividend yield, faster revenue growth and a higher ROCE, while KREBS BIOCHEMICALS & IND shows a lower P/E. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

JUBLPHARMA leads 8; KREBSBIO leads 3 of 11

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

JUBLPHARMAKREBSBIO

Valuation lens

What price are you paying?

Market CapContext only
₹14,774 Cr
₹121 Cr
P/E RatioKREBSBIO has the lower reading
40.9x
0x
P/B RatioKREBSBIO has the lower reading
2.03x
0x
EPSJUBLPHARMA has the higher reading
₹3.55
₹-1.15
Book ValueContext only
₹445.48
Dividend YieldJUBLPHARMA has the higher reading
0.57%
0%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
JUBLPHARMA is the larger company
₹14,774 Cr vs ₹121 Cr
P/E Ratio
KREBSBIO has a lower P/E
0x vs 40.9x
P/B Ratio
KREBSBIO has a lower P/B
0x vs 2.03x
EPS
JUBLPHARMA has higher earnings per share
₹3.55 vs ₹-1.15
Dividend Yield
JUBLPHARMA has a higher dividend yield
0.57% vs 0%
Revenue Growth (TTM YoY)
JUBLPHARMA has faster revenue growth
18.7% vs 11.6%
EPS Growth (TTM YoY)
KREBSBIO has faster EPS growth
0% vs -22.4%
Qtr Sales Growth
JUBLPHARMA has stronger quarterly sales growth
3,222.5% vs -70.57%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricJUBLPHARMAKREBSBIO
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricJUBLPHARMAKREBSBIO
Live Price₹924.5₹55.95
Day Change1.83%2.66%
Volume4.98 L5,830
52-Week High₹1,183₹82.49
52-Week Low₹786.05₹38.33
Distance from 52W High-21.85%-32.17%

Valuation

MetricJUBLPHARMAKREBSBIO
Market Cap₹14,774 Cr₹121 Cr
P/E Ratio40.9x0x
P/B Ratio2.03x0x
EPS₹3.55₹-1.15
Book Value₹445.48
Dividend Yield0.57%0%

Growth

MetricJUBLPHARMAKREBSBIO
Revenue Growth (TTM YoY)18.7%11.6%
EPS Growth (TTM YoY)-22.4%0%
Qtr Sales Growth3,222.5%-70.57%
Qtr Profit Growth672.6%85.33%

Profitability & Leverage

MetricJUBLPHARMAKREBSBIO
ROE5.6%
ROCE6.19%-15.89%
Net Margin5.28%-71.35%
Operating Margin9.98%-41.49%
Debt to Equity0.45x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricJUBLPHARMAKREBSBIO
Promoter Holding44.39%72.74%
FII Holding15.87% 0.03 pp0.5%
DII Holding12.4% 0.78 pp0%
Public Holding23.5% 0.74 pp26.76%

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: JUBILANT PHARMOVA and KREBS BIOCHEMICALS & IND.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.